Stemaxon

stemaxon aims to be the world leader and defined reference for all r&d; related to neurodegenerative diseases, mainly, sporadic alzheimer’ disease (ad). strong of its results after years of research by world renowned dr. gilbert bernier, stemaxon provides a new platform (patent pending) for the pharmaceutical industry to test their lead compounds against ad. this unique platform greatly increases the efficiency to validate existing molecules for drug development and treatment. additionally, stemaxon wants to democratize the access to research using pluripotent stem cell-derived human neurons for academic laboratories, research entities and costumers at large. stemaxon has created a ready kit mix with protocol, which accelerates any types of neuronal research, including neuron silicon interface. the simplicity of use of the product will enable anyone, to grow and study normal and disease-affected human neurons in vitro.